Home » Prostate Health Index (phi)

The Prostate Health Index (phi ) Can Help Reduce Unnecessary Biopsies

The Prostate Health Index is an FDA approved blood test that can help differentiate prostate cancer from benign conditions in men with elevated PSA. The Prostate Health Index utilizes three different PSA markers (PSA, freePSA, and p2PSA) as part of a sophisticated algorithm to more reliably determine the probability of cancer in patients with elevated PSA levels and can help men and their physicians decide if a prostate biopsy is indicated. (2-5)

The Prostate Health Index is now available through the AVRT telehealth program. AVRT™ is a comprehensive telehealth program that uses advanced diagnostics, evidence based clinical protocols and online physician supervision to help patients stay well and reduce the risk of developing cancer and other chronic diseases. AVRT is run by The Care Oncology Group, a team of experienced doctors and cancer specialists who can help you understand early warning signals for cancer and chronic diseases.

The Prostate Health Index can be ordered by a physician through the AVRT telehealth program. 

Please complete the form below to get started.

PHI Patient Eligibility

  • This field is for validation purposes and should be left unchanged.

​Indications for use

Prostrate cancer: why early detection matters - man looking seriously at camera with text that says 'Early detection's five year survival rate is 100% while late detection's five year survival rate is 30%."

Male patients may be a candidate for the Prostate Index Test if they are age 50 years and older with an elevated PSA between 4ng/ml and 10ng/ml. Peer-reviewed published studies support the use of Prostate Health Index in men with total PSA values as low as 2 ng/ml (1-4). The Prostate Health Index is included in the National Comprehensive Cancer Network (NCCN) Guideline for Prostate Cancer Early Detection as a blood test to improve specificity for prostate cancer detection. (6)

References​

  1.  Biddle C, Brasel A, Underwood W 3rd, et al. Experiences of Uncertainty in Men With an Elevated PSA. Am J Mens Health. 2016;11(1):24-34.
  2. Catalona WJ, Partin AW, Sanda MG, et al. A Multi-Center Study of [−2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. The Journal of Urology. 2011;185(5):1650-1655. 
  3. Loeb S, Sanda MG, Broyles DL, et al. The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. The Journal of Urology. 2015;193(4):1163-1169 
  4. Huang YQ, Sun T, Zhong WD, et al. Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. Am J Clin Exp Urol  2014;2(4):343-350 
  5. Lepor A, Catalona WJ, Loeb S. The Prostate Health Index: Its Utility In Prostate Cancer Detection. The Urologic Clinics of North America. 2016;43(1):1-6. 
  6. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Version 2.2018 – April 5, 2018